Supplementary

# Tables

### Table S1

| Variable | Not tested | Tested | p value | Logistic regression odds-ratio  [95%CI] |
| --- | --- | --- | --- | --- |
|  | n=7480 | n=649 |  |  |
| Age | 63 [57.2-68.9] | 61.2 [55.7-67.1] | <0.0001 \* | 0.98 [0.97-0.99] |
| *Missing* | 10 | 2 |  |  |
| Gender |  |  | 0.6065 |  |
| Female | 4388 (91.9%) | 388 (8.1%) |  |  |
| Male | 3092 (92.2%) | 261 (7.8%) |  | 0.95 [0.81-1.12] |
| *Missing* | 0 | 0 |  |  |
| City of living |  |  | <0.0001 \* |  |
| Montréal | 5014 (90.7%) | 515 (9.3%) |  |  |
| Other | 2466 (94.8%) | 134 (5.2%) |  | 0.53 [0.43-0.64] |
| *Missing* | 0 | 0 |  |  |
| Body mass index | 26.1 [23.4-29.5] | 26.5 [23.6-30.2] | 0.0223 | 1.02 [1-1.03] |
| *Missing* | 649 | 60 |  |  |
| International travel |  |  | 0.0014 \* |  |
| No | 5833 (92.6%) | 465 (7.4%) |  |  |
| Yes | 1480 (90.2%) | 161 (9.8%) |  | 1.36 [1.13-1.64] |
| *Missing* | 167 | 23 |  |  |
| Medical worker |  |  | <0.0001 \* |  |
| No | 7061 (93.5%) | 494 (6.5%) |  |  |
| Yes | 285 (68%) | 134 (32%) |  | 6.72 [5.36-8.4] |
| *Missing* | 134 | 21 |  |  |
| Essential Worker |  |  | 0.63 |  |
| No | 6975 (92.0%) | 602 (8.0%) |  |  |
| Yes | 505 (91.5%) | 47 (8.5%) |  | 1.08 [0.79-1.47] |
| *Missing* | 0 | 0 |  |  |
| Dwelling |  |  | 0.0024 \* |  |
| House | 5425 (92.7%) | 427 (7.3%) |  |  |
| Other | 1896 (90.6%) | 197 (9.4%) |  | 1.32 [1.1-1.57] |
| *Missing* | 159 | 25 |  |  |
| Contact with COVID-19 positive individual |  |  | <0.0001 \* |  |
| No | 6434 (93.9%) | 418 (6.1%) |  |  |
| Yes | 166 (57.4%) | 123 (42.6%) |  | 11.41 [8.84-14.68] |
| *Missing* | 880 | 109 |  |  |
| Smoking status |  |  | 0.1011 |  |
| Non-smoker | 6785 (92.3%) | 565 (7.7%) |  | 0.77 [0.58-1.05] |
| Daily/occasionally | 491 (90.3%) | 53 (9.7%) |  |  |
| *Missing* | 204 | 31 |  |  |
| Pets at home |  |  | 0.693 |  |
| No | 4460 (92.2%) | 376 (7.8%) |  |  |
| Yes | 2753 (92%) | 241 (8%) |  | 1.04 [0.88-1.23] |
| *Missing* | 267 | 32 |  |  |
| Number of children at home |  |  | 0.0618 |  |
| 0 | 3311 (90.8%) | 334 (9.2%) |  |  |
| One or more | 811 (92.9%) | 62 (7.1%) |  | 0.76 [0.57-1] |
| *Missing* | 3358 | 253 |  |  |
| Annual household income |  |  | 0.2254 |  |
| <$100,000 | 4077 (92.4%) | 333 (7.6%) |  |  |
| >$100,000 | 2279 (91.6%) | 209 (8.4%) |  | 1.12 [0.94-1.34] |
| *Missing* | 1124 | 107 |  |  |
| Medical precondition \*\*\* |  |  | 0.0024 \* |  |
| No | 3965 (93%) | 297 (7%) |  |  |
| Yes | 3346 (91.2%) | 324 (8.8%) |  | 1.29 [1.1-1.52] |
| *Missing* | 169 | 28 |  |  |
| Cancer disease |  |  | 0.4766 |  |
| No | 6421 (92.3%) | 536 (7.7%) |  |  |
| Yes | 881 (91.6%) | 81 (8.4%) |  | 1.1 [0.86-1.4] |
| *Missing* | 178 | 32 |  |  |
| Cancer treatment |  |  | 0.8279 |  |
| No | 7198 (92.2%) | 607 (7.8%) |  |  |
| Yes | 104 (91.2%) | 10 (8.8%) |  | 1.14 [0.56-2.09] |
| *Missing* | 178 | 32 |  |  |
| Diabetic |  |  | 0.2511 |  |
| No | 6576 (92.3%) | 550 (7.7%) |  |  |
| Yes | 712 (91%) | 70 (9%) |  | 1.18 [0.9-1.51] |
| *Missing* | 192 | 29 |  |  |
| Currently treated for diabetes |  |  | 0.7566 |  |
| No | 6651 (92.1%) | 569 (7.9%) |  |  |
| Yes | 632 (92.5%) | 51 (7.5%) |  | 0.94 [0.69-1.26] |
| *Missing* | 197 | 29 |  |  |
| Heart or circulatory condition |  |  | 0.6042 |  |
| No | 4969 (92.1%) | 429 (7.9%) |  |  |
| Yes | 2340 (92.4%) | 192 (7.6%) |  | 0.95 [0.79-1.13] |
| *Missing* | 171 | 28 |  |  |
| High blood pressure |  |  | 0.7556 |  |
| No | 5342 (92.1%) | 458 (7.9%) |  |  |
| Yes | 1967 (92.3%) | 163 (7.7%) |  | 0.97 [0.8-1.16] |
| *Missing* | 171 | 28 |  |  |
| Myocardial infarction |  |  | 0.6077 |  |
| No | 7117 (92.2%) | 602 (7.8%) |  |  |
| Yes | 192 (91%) | 19 (9%) |  | 1.17 [0.7-1.84] |
| *Missing* | 171 | 28 |  |  |
| Heart failure |  |  | 0.7958 |  |
| No | 7263 (92.2%) | 617 (7.8%) |  |  |
| Yes | 46 (92%) | 4 (8%) |  | 1.14 [0.37-2.7]\*\* |
| *Missing* | 171 | 28 |  |  |
| Coronary heart disease |  |  | 0.4798 |  |
| No | 7190 (92.2%) | 608 (7.8%) |  |  |
| Yes | 119 (90.2%) | 13 (9.8%) |  | 1.29 [0.69-2.22] |
| *Missing* | 171 | 28 |  |  |
| Atrial fibrillation |  |  | 0.4554 |  |
| No | 7106 (92.2%) | 600 (7.8%) |  |  |
| Yes | 203 (90.6%) | 21 (9.4%) |  | 1.23 [0.75-1.89] |
| *Missing* | 171 | 28 |  |  |
| Angina |  |  | 0.4369 |  |
| No | 7182 (92.2%) | 607 (7.8%) |  |  |
| Yes | 127 (90.1%) | 14 (9.9%) |  | 1.3 [0.71-2.2] |
| *Missing* | 171 | 28 |  |  |
| Valvular heart disease |  |  | 0.3435 |  |
| No | 7211 (92.1%) | 616 (7.9%) |  |  |
| Yes | 98 (95.1%) | 5 (4.9%) |  | 0.6 [0.21-1.33] |
| *Missing* | 171 | 28 |  |  |
| High blood pressure treatment |  |  | 1 |  |
| No | 5342 (92.1%) | 458 (7.9%) |  |  |
| Yes | 1800 (92.1%) | 155 (7.9%) |  | 1 [0.83-1.21] |
| *Missing* | 338 | 36 |  |  |
| Myocardial infarction treatment |  |  | 0.7607 |  |
| No | 7117 (92.2%) | 602 (7.8%) |  |  |
| Yes | 150 (93.2%) | 11 (6.8%) |  | 0.87 [0.44-1.53] |
| *Missing* | 213 | 36 |  |  |
| Heart failure treatment |  |  | 1 |  |
| No | 7263 (92.2%) | 617 (7.8%) |  |  |
| Yes | 42 (93.3%) | 3 (6.7%) |  | 0.97 [0.26-2.52]\*\* |
| *Missing* | 175 | 29 |  |  |
| Coronary heart disease treatment |  |  | 0.8123 |  |
| No | 7190 (92.2%) | 608 (7.8%) |  |  |
| Yes | 103 (91.2%) | 10 (8.8%) |  | 1.15 [0.56-2.1] |
| *Missing* | 187 | 31 |  |  |
| Atrial fibrillation treatment |  |  | 0.7926 |  |
| No | 7106 (92.2%) | 600 (7.8%) |  |  |
| Yes | 159 (91.4%) | 15 (8.6%) |  | 1.12 [0.63-1.85] |
| *Missing* | 215 | 34 |  |  |
| Angina treatment |  |  | 0.7015 |  |
| No | 7182 (92.2%) | 607 (7.8%) |  |  |
| Yes | 98 (90.7%) | 10 (9.3%) |  | 1.21 [0.59-2.21] |
| *Missing* | 200 | 32 |  |  |
| Valvular heart disease treatment |  |  | 0.0471 |  |
| No | 7211 (92.1%) | 616 (7.9%) |  |  |
| Yes | 45 (100%) | 0 (0%) |  | - |
| *Missing* | 224 | 33 |  |  |
| Respiratory system condition |  |  | <0.0001 \* |  |
| No | 5704 (92.9%) | 434 (7.1%) |  |  |
| Yes | 1602 (89.5%) | 187 (10.5%) |  | 1.53 [1.28-1.83] |
| *Missing* | 174 | 28 |  |  |
| Asthma |  |  | <0.0001 \* |  |
| No | 6493 (92.7%) | 512 (7.3%) |  |  |
| Yes | 813 (88.2%) | 109 (11.8%) |  | 1.7 [1.36-2.11] |
| *Missing* | 174 | 28 |  |  |
| COPD |  |  | <0.0001 \* |  |
| No | 7169 (92.4%) | 590 (7.6%) |  |  |
| Yes | 137 (81.5%) | 31 (18.5%) |  | 2.75 [1.81-4.04] |
| *Missing* | 174 | 28 |  |  |
| Interstitial lung disease |  |  | 0.3603 |  |
| No | 7292 (92.2%) | 619 (7.8%) |  |  |
| Yes | 14 (87.5%) | 2 (12.5%) |  | 2.03 [0.4-6.63]\*\* |
| *Missing* | 174 | 28 |  |  |
| Chronic bronchitis |  |  | <0.0001 \* |  |
| No | 7174 (92.3%) | 595 (7.7%) |  |  |
| Yes | 132 (83.5%) | 26 (16.5%) |  | 2.37 [1.51-3.58] |
| *Missing* | 174 | 28 |  |  |
| Cystic fibrosis |  |  | 1 |  |
| No | 7305 (92.2%) | 621 (7.8%) |  |  |
| Yes | 1 (100%) | 0 (0%) |  | - |
| *Missing* | 174 | 28 |  |  |
| Emphysema |  |  | 0.1397 |  |
| No | 7254 (92.2%) | 613 (7.8%) |  |  |
| Yes | 52 (86.7%) | 8 (13.3%) |  | 1.91 [0.86-3.76]\*\* |
| *Missing* | 174 | 28 |  |  |
| Sleep apnea |  |  | 0.0471 |  |
| No | 6578 (92.4%) | 543 (7.6%) |  |  |
| Yes | 728 (90.3%) | 78 (9.7%) |  | 1.3 [1-1.66] |
| *Missing* | 174 | 28 |  |  |
| Asthma treatment |  |  | <0.0001 \* |  |
| No | 6493 (92.7%) | 512 (7.3%) |  |  |
| Yes | 543 (87.6%) | 77 (12.4%) |  | 1.8 [1.38-2.31] |
| *Missing* | 444 | 60 |  |  |
| COPD treatment |  |  | <0.0001 \* |  |
| No | 7169 (92.4%) | 590 (7.6%) |  |  |
| Yes | 89 (80.2%) | 22 (19.8%) |  | 3 [1.83-4.73] |
| *Missing* | 222 | 37 |  |  |
| Interstitial lung disease treatment |  |  | 0.1819 |  |
| No | 7292 (92.2%) | 619 (7.8%) |  |  |
| Yes | 8 (80%) | 2 (20%) |  | 3.46 [0.65-12.56]\*\* |
| *Missing* | 180 | 28 |  |  |
| Chronic bronchitis treatment |  |  | 0.1755 |  |
| No | 7174 (92.3%) | 595 (7.7%) |  |  |
| Yes | 62 (87.3%) | 9 (12.7%) |  | 1.75 [0.81-3.36] |
| *Missing* | 244 | 45 |  |  |
| Emphysema treatment |  |  | 0.7663 |  |
| No | 7254 (92.2%) | 613 (7.8%) |  |  |
| Yes | 37 (94.9%) | 2 (5.1%) |  | 0.79 [0.16-2.35]\*\* |
| *Missing* | 189 | 34 |  |  |
| Sleep apnea treatment |  |  | 0.0235 |  |
| No | 6578 (92.4%) | 543 (7.6%) |  |  |
| Yes | 530 (89.7%) | 61 (10.3%) |  | 1.39 [1.05-1.83] |
| *Missing* | 372 | 45 |  |  |
| Gastrointestinal condition |  |  | 0.1149 |  |
| No | 6692 (92.3%) | 556 (7.7%) |  |  |
| Yes | 613 (90.5%) | 64 (9.5%) |  | 1.26 [0.95-1.64] |
| *Missing* | 175 | 29 |  |  |
| Crohn's disease |  |  | 1 |  |
| No | 7255 (92.2%) | 616 (7.8%) |  |  |
| Yes | 50 (92.6%) | 4 (7.4%) |  | 1.05 [0.34-2.48]\*\* |
| *Missing* | 175 | 29 |  |  |
| Ulcerative colitis |  |  | 0.7509 |  |
| No | 7230 (92.2%) | 615 (7.8%) |  |  |
| Yes | 75 (93.8%) | 5 (6.2%) |  | 0.78 [0.27-1.76] |
| *Missing* | 175 | 29 |  |  |
| Irritable bowel syndrome |  |  | 0.0662 |  |
| No | 6848 (92.3%) | 569 (7.7%) |  |  |
| Yes | 457 (90%) | 51 (10%) |  | 1.34 [0.98-1.8] |
| *Missing* | 175 | 29 |  |  |
| Celiac disease |  |  | 0.617 |  |
| No | 7255 (92.2%) | 615 (7.8%) |  |  |
| Yes | 50 (90.9%) | 5 (9.1%) |  | 1.28 [0.47-2.85]\*\* |
| *Missing* | 175 | 29 |  |  |
| Crohn's disease treatment |  |  | 1 |  |
| No | 7255 (92.2%) | 616 (7.8%) |  |  |
| Yes | 37 (92.5%) | 3 (7.5%) |  | 1.1 [0.3-2.88]\*\* |
| *Missing* | 188 | 30 |  |  |
| Ulcerative colitis treatment |  |  | 0.6285 |  |
| No | 7230 (92.2%) | 615 (7.8%) |  |  |
| Yes | 58 (95.1%) | 3 (4.9%) |  | 0.7 [0.19-1.8]\*\* |
| *Missing* | 192 | 31 |  |  |
| Irritable bowel syndrome treatment |  |  | 0.0465 |  |
| No | 6848 (92.3%) | 569 (7.7%) |  |  |
| Yes | 108 (87.1%) | 16 (12.9%) |  | 1.78 [1.01-2.95] |
| *Missing* | 524 | 64 |  |  |
| Celiac disease treatment |  |  | 0.5307 |  |
| No | 7255 (92.2%) | 615 (7.8%) |  |  |
| Yes | 33 (89.2%) | 4 (10.8%) |  | 1.58 [0.51-3.84]\*\* |
| *Missing* | 192 | 30 |  |  |
| Liver or pancreas disease |  |  | 2e-04 \* |  |
| No | 6938 (92.4%) | 567 (7.6%) |  |  |
| Yes | 366 (87.4%) | 53 (12.6%) |  | 1.77 [1.3-2.37] |
| *Missing* | 176 | 29 |  |  |
| Liver cirrhosis |  |  | 1 |  |
| No | 7289 (92.2%) | 619 (7.8%) |  |  |
| Yes | 15 (93.8%) | 1 (6.2%) |  | 1.14 [0.13-4.58]\*\* |
| *Missing* | 176 | 29 |  |  |
| Chronic hepatitis |  |  | 0.667 |  |
| No | 7286 (92.2%) | 618 (7.8%) |  |  |
| Yes | 18 (90%) | 2 (10%) |  | 1.59 [0.32-5.04]\*\* |
| *Missing* | 176 | 29 |  |  |
| NAFLD / NASH |  |  | 3e-04 \* |  |
| No | 6962 (92.4%) | 570 (7.6%) |  |  |
| Yes | 342 (87.2%) | 50 (12.8%) |  | 1.79 [1.3-2.41] |
| *Missing* | 176 | 29 |  |  |
| Liver cirrhosis treatment |  |  | 1 |  |
| No | 7289 (92.2%) | 619 (7.8%) |  |  |
| Yes | 11 (91.7%) | 1 (8.3%) |  | 1.53 [0.17-6.44]\*\* |
| *Missing* | 180 | 29 |  |  |
| Chronic hepatitis treatment |  |  | 1 |  |
| No | 7286 (92.2%) | 618 (7.8%) |  |  |
| Yes | 11 (100%) | 0 (0%) |  | - |
| *Missing* | 183 | 31 |  |  |
| NAFLD / NASH treatment |  |  | 0.1919 |  |
| No | 6962 (92.4%) | 570 (7.6%) |  |  |
| Yes | 31 (86.1%) | 5 (13.9%) |  | 2.13 [0.76-4.89]\*\* |
| *Missing* | 487 | 74 |  |  |
| Renal disease |  |  | 0.22 |  |
| No | 7239 (92.1%) | 618 (7.9%) |  |  |
| Yes | 64 (97%) | 2 (3%) |  | 0.37 [0.06-1.17] |
| *Missing* | 177 | 29 |  |  |
| Acute renal failure |  |  | 0.3925 |  |
| No | 7285 (92.2%) | 620 (7.8%) |  |  |
| Yes | 18 (100%) | 0 (0%) |  | - |
| *Missing* | 177 | 29 |  |  |
| Chronic renal failure |  |  | 0.5879 |  |
| No | 7256 (92.2%) | 618 (7.8%) |  |  |
| Yes | 47 (95.9%) | 2 (4.1%) |  | 0.62 [0.13-1.82]\*\* |
| *Missing* | 177 | 29 |  |  |
| Acute renal failure treatment |  |  | 1 |  |
| No | 7285 (92.2%) | 620 (7.8%) |  |  |
| Yes | 10 (100%) | 0 (0%) |  | - |
| *Missing* | 185 | 29 |  |  |
| Chronic renal failure treatment |  |  | 0.1649 |  |
| No | 7256 (92.2%) | 618 (7.8%) |  |  |
| Yes | 28 (100%) | 0 (0%) |  | - |
| *Missing* | 196 | 31 |  |  |
| Mental health condition |  |  | 0.22 |  |
| No | 7239 (92.1%) | 618 (7.9%) |  |  |
| Yes | 64 (97%) | 2 (3%) |  | 0.37 [0.06-1.17] |
| *Missing* | 177 | 29 |  |  |
| Neurological condition |  |  | 0.0098 |  |
| No | 7218 (92.3%) | 605 (7.7%) |  |  |
| Yes | 83 (84.7%) | 15 (15.3%) |  | 2.16 [1.19-3.65] |
| *Missing* | 179 | 29 |  |  |
| Thrombotic stroke |  |  | 0.0653 |  |
| No | 7270 (92.2%) | 614 (7.8%) |  |  |
| Yes | 31 (83.8%) | 6 (16.2%) |  | 2.44 [0.95-5.35]\*\* |
| *Missing* | 179 | 29 |  |  |
| Hemorrhagic stroke |  |  | 0.3888 |  |
| No | 7286 (92.2%) | 618 (7.8%) |  |  |
| Yes | 15 (88.2%) | 2 (11.8%) |  | 1.9 [0.38-6.15]\*\* |
| *Missing* | 179 | 29 |  |  |
| Stroke |  |  | 0.123 |  |
| No | 7256 (92.2%) | 613 (7.8%) |  |  |
| Yes | 45 (86.5%) | 7 (13.5%) |  | 1.95 [0.83-3.99]\*\* |
| *Missing* | 179 | 29 |  |  |
| Multiple sclerosis |  |  | 0.0279 |  |
| No | 7262 (92.2%) | 612 (7.8%) |  |  |
| Yes | 39 (83%) | 8 (17%) |  | 2.55 [1.13-5.12]\*\* |
| *Missing* | 179 | 29 |  |  |
| Thrombotic stroke treatment |  |  | 0.0632 |  |
| No | 7270 (92.2%) | 614 (7.8%) |  |  |
| Yes | 23 (82.1%) | 5 (17.9%) |  | 2.77 [0.98-6.55]\*\* |
| *Missing* | 187 | 30 |  |  |
| Hemorrhagic stroke treatment |  |  | 0.1817 |  |
| No | 7286 (92.2%) | 618 (7.8%) |  |  |
| Yes | 8 (80%) | 2 (20%) |  | 3.46 [0.65-12.57]\*\* |
| *Missing* | 186 | 29 |  |  |
| Stroke treatment |  |  | 0.0585 |  |
| No | 7256 (92.2%) | 613 (7.8%) |  |  |
| Yes | 30 (83.3%) | 6 (16.7%) |  | 2.52 [0.98-5.54]\*\* |
| *Missing* | 194 | 30 |  |  |
| Multiple sclerosis treatment |  |  | 0.0801 |  |
| No | 7262 (92.2%) | 612 (7.8%) |  |  |
| Yes | 25 (83.3%) | 5 (16.7%) |  | 2.56 [0.91-5.99]\*\* |
| *Missing* | 193 | 32 |  |  |
| Arthritis disease |  |  | 0.7344 |  |
| No | 6213 (92.2%) | 524 (7.8%) |  |  |
| Yes | 1087 (91.9%) | 96 (8.1%) |  | 1.05 [0.83-1.31] |
| *Missing* | 180 | 29 |  |  |
| Rheumatoid arthritis |  |  | 0.9974 |  |
| No | 7024 (92.2%) | 596 (7.8%) |  |  |
| Yes | 276 (92%) | 24 (8%) |  | 1.02 [0.65-1.53] |
| *Missing* | 180 | 29 |  |  |
| Osteoarthritis |  |  | 0.1021 |  |
| No | 6975 (92.3%) | 583 (7.7%) |  |  |
| Yes | 325 (89.8%) | 37 (10.2%) |  | 1.36 [0.94-1.91] |
| *Missing* | 180 | 29 |  |  |
| Rheumatoid arthritis treatment |  |  | 0.8769 |  |
| No | 7173 (92.2%) | 609 (7.8%) |  |  |
| Yes | 117 (91.4%) | 11 (8.6%) |  | 1.11 [0.56-1.97] |
| *Missing* | 190 | 29 |  |  |
| Osteoarthritis treatment |  |  | 0.0046 |  |
| No | 7206 (92.3%) | 603 (7.7%) |  |  |
| Yes | 85 (84.2%) | 16 (15.8%) |  | 2.25 [1.26-3.75] |
| *Missing* | 189 | 30 |  |  |
| Bone and joint condition |  |  | 0.2549 |  |
| No | 6105 (92.3%) | 507 (7.7%) |  |  |
| Yes | 1195 (91.4%) | 113 (8.6%) |  | 1.14 [0.92-1.4] |
| *Missing* | 180 | 29 |  |  |
| Lupus |  |  | 0.404 |  |
| No | 7279 (92.2%) | 620 (7.8%) |  |  |
| Yes | 21 (100%) | 0 (0%) |  | - |
| *Missing* | 180 | 29 |  |  |
| Fibromyalgia |  |  | 0.0169 |  |
| No | 7144 (92.3%) | 597 (7.7%) |  |  |
| Yes | 156 (87.2%) | 23 (12.8%) |  | 1.76 [1.1-2.7] |
| *Missing* | 180 | 29 |  |  |
| Lupus treatment |  |  | 1 |  |
| No | 7279 (92.2%) | 620 (7.8%) |  |  |
| Yes | 11 (100%) | 0 (0%) |  | - |
| *Missing* | 190 | 29 |  |  |
| Fibromyalgia |  |  | 3e-04 \* |  |
| No | 7144 (92.3%) | 597 (7.7%) |  |  |
| Yes | 82 (82%) | 18 (18%) |  | 2.63 [1.52-4.3] |
| *Missing* | 254 | 34 |  |  |
| Skin condition |  |  | 0.3539 |  |
| No | 6150 (92.3%) | 513 (7.7%) |  |  |
| Yes | 1150 (91.5%) | 107 (8.5%) |  | 1.12 [0.89-1.38] |
| *Missing* | 180 | 29 |  |  |
| Eczema |  |  | 0.4662 |  |
| No | 6516 (92.3%) | 547 (7.7%) |  |  |
| Yes | 784 (91.5%) | 73 (8.5%) |  | 1.11 [0.85-1.42] |
| *Missing* | 180 | 29 |  |  |
| Psoriasis |  |  | 0.38 |  |
| No | 6864 (92.2%) | 577 (7.8%) |  |  |
| Yes | 436 (91%) | 43 (9%) |  | 1.17 [0.84-1.6] |
| *Missing* | 180 | 29 |  |  |
| Scleroderma |  |  | 1 |  |
| No | 7290 (92.2%) | 620 (7.8%) |  |  |
| Yes | 10 (100%) | 0 (0%) |  | - |
| *Missing* | 180 | 29 |  |  |
| Eczema treatment |  |  | 0.9341 |  |
| No | 6516 (92.3%) | 547 (7.7%) |  |  |
| Yes | 346 (92.5%) | 28 (7.5%) |  | 0.96 [0.64-1.4] |
| *Missing* | 618 | 74 |  |  |
| Psoriasis treatment |  |  | 0.0791 |  |
| No | 6864 (92.2%) | 577 (7.8%) |  |  |
| Yes | 208 (88.9%) | 26 (11.1%) |  | 1.49 [0.96-2.21] |
| *Missing* | 408 | 46 |  |  |
| Scleroderma treatment |  |  | 1 |  |
| No | 7290 (92.2%) | 620 (7.8%) |  |  |
| Yes | 4 (100%) | 0 (0%) |  | - |
| *Missing* | 186 | 29 |  |  |
| Immune system condition |  |  | 0.0539 |  |
| No | 7088 (92.3%) | 593 (7.7%) |  |  |
| Yes | 211 (88.7%) | 27 (11.3%) |  | 1.53 [0.99-2.26] |
| *Missing* | 181 | 29 |  |  |
| HIV |  |  | 0.4299 |  |
| No | 7278 (92.2%) | 617 (7.8%) |  |  |
| Yes | 21 (87.5%) | 3 (12.5%) |  | 1.92 [0.51-5.27]\*\* |
| *Missing* | 181 | 29 |  |  |
| Weakened/compromised immune system |  |  | 0.6762 |  |
| No | 7235 (92.2%) | 613 (7.8%) |  |  |
| Yes | 64 (90.1%) | 7 (9.9%) |  | 1.29 [0.54-2.64] |
| *Missing* | 181 | 29 |  |  |
| Hashimoto’s thyroiditis, Sjögren’s syndrome, Ankylosing spondylitis |  |  | 0.1149 |  |
| No | 7170 (92.2%) | 603 (7.8%) |  |  |
| Yes | 129 (88.4%) | 17 (11.6%) |  | 1.57 [0.91-2.54] |
| *Missing* | 181 | 29 |  |  |
| HIV treatment |  |  | 0.2455 |  |
| No | 7278 (92.2%) | 617 (7.8%) |  |  |
| Yes | 19 (86.4%) | 3 (13.6%) |  | 2.12 [0.56-5.88]\*\* |
| *Missing* | 183 | 29 |  |  |
| Weakened/compromised immune system treatment |  |  | 0.5367 |  |
| No | 7235 (92.2%) | 613 (7.8%) |  |  |
| Yes | 34 (89.5%) | 4 (10.5%) |  | 1.54 [0.49-3.72]\*\* |
| *Missing* | 211 | 32 |  |  |
| Hashimoto’s thyroiditis, Sjögren’s syndrome, Ankylosing spondylitis treatment |  |  | 0.1488 |  |
| No | 7170 (92.2%) | 603 (7.8%) |  |  |
| Yes | 105 (88.2%) | 14 (11.8%) |  | 1.59 [0.86-2.69] |
| *Missing* | 205 | 32 |  |  |
| Seasonal influenza vaccination in 2019 / 2020 |  |  | 0.2302 |  |
| No | 4257 (92.4%) | 348 (7.6%) |  |  |
| Yes | 2985 (91.7%) | 271 (8.3%) |  | 1.11 [0.94-1.31] |
| *Missing* | 238 | 30 |  |  |
| BCG vaccination |  |  | 0.2727 |  |
| Yes | 3278 (91.6%) | 299 (8.4%) |  | 1.12 [0.92-1.35] |
| No | 2303 (92.5%) | 188 (7.5%) |  |  |
| *Missing* | 1899 | 162 |  |  |
| Received an organ, bone marrow, or stem cell transplant |  |  | 0.3215 |  |
| No | 7198 (92.2%) | 606 (7.8%) |  |  |
| Yes | 29 (87.9%) | 4 (12.1%) |  | 1.81 [0.58-4.44]\*\* |
| *Missing* | 253 | 39 |  |  |
| ACE-inhibitors class |  |  | 0.8699 |  |
| No | 6628 (92%) | 577 (8%) |  |  |
| Yes | 852 (92.2%) | 72 (7.8%) |  | 0.97 [0.75-1.24] |
| *Missing* | 0 | 0 |  |  |
| Angiotensin II Receptor Blockers |  |  | 0.3509 |  |
| No | 6538 (91.9%) | 576 (8.1%) |  |  |
| Yes | 942 (92.8%) | 73 (7.2%) |  | 0.88 [0.68-1.13] |
| *Missing* | 0 | 0 |  |  |
| Antibiotics |  |  | <0.0001 \* |  |
| No | 6326 (93%) | 479 (7%) |  |  |
| Yes | 1154 (87.2%) | 170 (12.8%) |  | 1.95 [1.61-2.34] |
| *Missing* | 0 | 0 |  |  |
| Antivirals |  |  | 0.3351 |  |
| No | 7260 (92.1%) | 625 (7.9%) |  |  |
| Yes | 220 (90.2%) | 24 (9.8%) |  | 1.27 [0.8-1.91] |
| *Missing* | 0 | 0 |  |  |
| Allergy medications |  |  | <0.0001 \* |  |
| No | 5925 (92.6%) | 471 (7.4%) |  |  |
| Yes | 1555 (89.7%) | 178 (10.3%) |  | 1.44 [1.2-1.72] |
| *Missing* | 0 | 0 |  |  |
| Androgen deprivation therapy |  |  | 0.4363 |  |
| No | 7430 (92%) | 647 (8%) |  |  |
| Yes | 50 (96.2%) | 2 (3.8%) |  | 0.57 [0.12-1.67]\*\* |
| *Missing* | 0 | 0 |  |  |
| Asthma medications |  |  | <0.0001 \* |  |
| No | 6742 (92.5%) | 545 (7.5%) |  |  |
| Yes | 738 (87.6%) | 104 (12.4%) |  | 1.74 [1.39-2.17] |
| *Missing* | 0 | 0 |  |  |
| Immunosuppressive/immunomodulatory medication |  |  | 0.0349 |  |
| No | 7139 (92.2%) | 607 (7.8%) |  |  |
| Yes | 341 (89%) | 42 (11%) |  | 1.45 [1.03-1.99] |
| *Missing* | 0 | 0 |  |  |
| Blood thinners |  |  | 0.3793 |  |
| No | 7075 (92.1%) | 608 (7.9%) |  |  |
| Yes | 405 (90.8%) | 41 (9.2%) |  | 1.18 [0.83-1.62] |
| *Missing* | 0 | 0 |  |  |
| Non-steroidal anti-inflammatory drugs |  |  | 0.0497 |  |
| No | 4223 (92.5%) | 340 (7.5%) |  |  |
| Yes | 3257 (91.3%) | 309 (8.7%) |  | 1.18 [1-1.38] |
| *Missing* | 0 | 0 |  |  |
| Other pain/fever relievers |  |  | 3e-04 \* |  |
| Yes | 4198 (91.1%) | 412 (8.9%) |  | 1.36 [1.15-1.61] |
| No | 3282 (93.3%) | 237 (6.7%) |  |  |
| *Missing* | 0 | 0 |  |  |
| Anosmia |  |  | <0.0001 \* |  |
| No | 7150 (92.7%) | 564 (7.3%) |  |  |
| Yes | 267 (78.8%) | 72 (21.2%) |  | 3.42 [2.58-4.47] |
| *Missing* | 63 | 13 |  |  |
| Ageusia |  |  | <0.0001 \* |  |
| No | 7138 (92.7%) | 566 (7.3%) |  |  |
| Yes | 279 (79.9%) | 70 (20.1%) |  | 3.16 [2.39-4.14] |
| *Missing* | 63 | 13 |  |  |
| Anosmia or ageusia |  |  | <0.0001 \* |  |
| No | 7069 (92.8%) | 551 (7.2%) |  |  |
| Yes | 348 (80.4%) | 85 (19.6%) |  | 3.13 [2.42-4.02] |
| *Missing* | 63 | 13 |  |  |
| Wet cough |  |  | <0.0001 \* |  |
| No | 6845 (92.7%) | 543 (7.3%) |  |  |
| Yes | 570 (86%) | 93 (14%) |  | 2.06 [1.62-2.59] |
| *Missing* | 65 | 13 |  |  |
| Dry cough |  |  | <0.0001 \* |  |
| No | 6787 (93.3%) | 484 (6.7%) |  |  |
| Yes | 630 (80.6%) | 152 (19.4%) |  | 3.38 [2.76-4.12] |
| *Missing* | 63 | 13 |  |  |
| Cough |  |  | <0.0001 \* |  |
| No | 6394 (93.6%) | 438 (6.4%) |  |  |
| Yes | 1021 (83.8%) | 198 (16.2%) |  | 2.83 [2.36-3.39] |
| *Missing* | 65 | 13 |  |  |
| Fatigue |  |  | <0.0001 \* |  |
| No | 7055 (93%) | 531 (7%) |  |  |
| Yes | 362 (77.4%) | 106 (22.6%) |  | 3.89 [3.07-4.9] |
| *Missing* | 63 | 12 |  |  |
| Loss of appetite |  |  | <0.0001 \* |  |
| No | 7347 (92.3%) | 611 (7.7%) |  |  |
| Yes | 70 (72.9%) | 26 (27.1%) |  | 4.47 [2.78-6.97] |
| *Missing* | 63 | 12 |  |  |
| Fever |  |  | <0.0001 \* |  |
| No | 6231 (93.5%) | 432 (6.5%) |  |  |
| Yes | 792 (83.1%) | 161 (16.9%) |  | 2.93 [2.41-3.56] |
| *Missing* | 457 | 56 |  |  |
| Rhinitis |  |  | <0.0001 \* |  |
| No | 7266 (92.3%) | 607 (7.7%) |  |  |
| Yes | 150 (83.3%) | 30 (16.7%) |  | 2.39 [1.58-3.52] |
| *Missing* | 64 | 12 |  |  |
| Sinus pain |  |  | <0.0001 \* |  |
| No | 7313 (92.4%) | 603 (7.6%) |  |  |
| Yes | 102 (75.6%) | 33 (24.4%) |  | 3.92 [2.59-5.79] |
| *Missing* | 65 | 13 |  |  |
| Ear pain |  |  | 0.1122 |  |
| No | 7374 (92.1%) | 629 (7.9%) |  |  |
| Yes | 43 (86%) | 7 (14%) |  | 2.02 [0.85-4.15]\*\* |
| *Missing* | 63 | 13 |  |  |
| Sore throat |  |  | <0.0001 \* |  |
| No | 7282 (92.4%) | 599 (7.6%) |  |  |
| Yes | 135 (78.5%) | 37 (21.5%) |  | 3.33 [2.26-4.79] |
| *Missing* | 63 | 13 |  |  |
| Hoarseness |  |  | <0.0001 \* |  |
| No | 6008 (93.4%) | 422 (6.6%) |  |  |
| Yes | 1408 (86.8%) | 215 (13.2%) |  | 2.17 [1.82-2.58] |
| *Missing* | 64 | 12 |  |  |
| Shortness of breath or difficulty breathing |  |  | <0.0001 \* |  |
| No | 6323 (93.7%) | 424 (6.3%) |  |  |
| Yes | 1093 (83.7%) | 213 (16.3%) |  | 2.91 [2.43-3.46] |
| *Missing* | 64 | 12 |  |  |
| Headache |  |  | <0.0001 \* |  |
| No | 7207 (92.7%) | 570 (7.3%) |  |  |
| Yes | 209 (75.7%) | 67 (24.3%) |  | 4.05 [3.02-5.38] |
| *Missing* | 64 | 12 |  |  |
| General muscle and/or joint aches and pains |  |  | <0.0001 \* |  |
| No | 7214 (92.5%) | 586 (7.5%) |  |  |
| Yes | 201 (79.8%) | 51 (20.2%) |  | 3.12 [2.25-4.26] |
| *Missing* | 65 | 12 |  |  |
| Chills or shivering |  |  | <0.0001 \* |  |
| No | 6246 (93.5%) | 432 (6.5%) |  |  |
| Yes | 1171 (85.1%) | 205 (14.9%) |  | 2.53 [2.12-3.02] |
| *Missing* | 63 | 12 |  |  |
| Diarrhea |  |  | <0.0001 \* |  |
| No | 7328 (92.3%) | 609 (7.7%) |  |  |
| Yes | 89 (76.7%) | 27 (23.3%) |  | 3.65 [2.31-5.58] |
| *Missing* | 63 | 13 |  |  |
| Vomiting |  |  | <0.0001 \* |  |
| No | 7210 (92.4%) | 592 (7.6%) |  |  |
| Yes | 206 (82.4%) | 44 (17.6%) |  | 2.6 [1.84-3.6] |
| *Missing* | 64 | 13 |  |  |
| Nausea |  |  | <0.0001 \* |  |
| No | 6676 (93.1%) | 492 (6.9%) |  |  |
| Yes | 741 (83.6%) | 145 (16.4%) |  | 2.66 [2.17-3.24] |
| *Missing* | 63 | 12 |  |  |

ACE: Angiotensin converting enzyme; BCG: Bacillus Calmette–Guérin; CI: confidence interval; COPD: Chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-Alcoholic Steatohepatitis

\* significant p-values after the Benjamini & Hochberg step-up false discovery rate-controlling procedure

\*\* Expected < 5 individuals: Firth's bias-Reduced penalized-likelihood logistic regression

\*\*\* medical condition currently treated among the following list: cardiovascular diseases (HBP, coronary artery disease,..), auto-immune diseases, diabetes, infectious disease, gastrointestinal and liver diseases, cancers, renal diseases.

### Table S2

| Variable | Negative | Positive | p value | Logistic regression odds-ratio  [95%CI] |
| --- | --- | --- | --- | --- |
|  | n=608 | n=41 |  |  |
| Age | 61.6 [56.1-67.3] | 56.6 [54.8-60.9] | 8e-04 \* | 0.92 [0.88-0.97] |
| *Missing* | 2 | 0 |  |  |
| Gender |  |  | 0.0215 |  |
| Female | 356 (91.8%) | 32 (8.2%) |  |  |
| Male | 252 (96.6%) | 9 (3.4%) |  | 0.4 [0.18-0.81] |
| *Missing* | 0 | 0 |  |  |
| City of living |  |  | 1 |  |
| Montréal | 482 (93.6%) | 33 (6.4%) |  |  |
| Other | 126 (94%) | 8 (6%) |  | 0.93 [0.39-1.96] |
| *Missing* | 0 | 0 |  |  |
| Body mass index | 26.5 [23.6-30.2] | 26.5 [23.9-29] | 0.8382 | 0.99 [0.93-1.04] |
| *Missing* | 51 | 9 |  |  |
| International travel |  |  | 0.6503 |  |
| No | 437 (94%) | 28 (6%) |  |  |
| Yes | 149 (92.5%) | 12 (7.5%) |  | 1.26 [0.6-2.48] |
| *Missing* | 22 | 1 |  |  |
| Medical worker |  |  | <0.0001 \* |  |
| No | 477 (96.6%) | 17 (3.4%) |  |  |
| Yes | 111 (82.8%) | 23 (17.2%) |  | 5.81 [3.02-11.41] |
| *Missing* | 20 | 1 |  |  |
| Essential Worker |  |  | 0.76 |  |
| No | 563 (93.5%) | 39 (6.5%) |  |  |
| Yes | 45 (95.7%) | 2 (4.3%) |  | 0.78 [0.16-2.40] |
| *Missing* | 0 | 0 |  |  |
| Dwelling |  |  | 0.964 |  |
| House | 399 (93.4%) | 28 (6.6%) |  |  |
| Other | 185 (93.9%) | 12 (6.1%) |  | 0.92 [0.44-1.82] |
| *Missing* | 24 | 1 |  |  |
| Contact with COVID-19 positive individual |  |  | <0.0001 \* |  |
| No | 408 (97.6%) | 10 (2.4%) |  |  |
| Yes | 99 (80.5%) | 24 (19.5%) |  | 9.89 [4.71-22.3] |
| *Missing* | 101 | 8 |  |  |
| Blood type |  |  | 0.8411 |  |
| O | 188 (94.5%) | 11 (5.5%) |  | 0.78 [0.34-1.77]\*\* |
| A | 173 (93%) | 13 (7%) |  |  |
| AB or B | 68 (93.2%) | 5 (6.8%) |  | 1.03 [0.34-2.76]\*\* |
| *Missing* | 179 | 12 |  |  |
| Smoking status |  |  | 0.2401 |  |
| Non smoker | 526 (93.1%) | 39 (6.9%) |  | 2.63 [0.68-23.61]\*\* |
| Daily/occasionally | 52 (98.1%) | 1 (1.9%) |  |  |
| *Missing* | 30 | 1 |  |  |
| Pets at home |  |  | 1 |  |
| No | 352 (93.6%) | 24 (6.4%) |  |  |
| Yes | 225 (93.4%) | 16 (6.6%) |  | 1.04 [0.53-1.99] |
| *Missing* | 31 | 1 |  |  |
| Number of children at home |  |  | 0.7807 |  |
| 0 | 311 (93.1%) | 23 (6.9%) |  |  |
| One or more | 59 (95.2%) | 3 (4.8%) |  | 0.78 [0.2-2.21]\*\* |
| *Missing* | 238 | 15 |  |  |
| Annual household income |  |  | 0.0465 |  |
| <$100,000 | 317 (95.2%) | 16 (4.8%) |  |  |
| >$100,000 | 189 (90.4%) | 20 (9.6%) |  | 2.1 [1.06-4.2] |
| *Missing* | 102 | 5 |  |  |
| Medical precondition \*\*\* |  |  | 0.0371 |  |
| Yes | 310 (95.7%) | 14 (4.3%) |  | 0.47 [0.23-0.91] |
| No | 271 (91.2%) | 26 (8.8%) |  |  |
| *Missing* | 27 | 1 |  |  |
| Cancer disease |  |  | 1 |  |
| No | 502 (93.7%) | 34 (6.3%) |  |  |
| Yes | 76 (93.8%) | 5 (6.2%) |  | 0.97 [0.33-2.35] |
| *Missing* | 30 | 2 |  |  |
| Cancer treatment |  |  | 1 |  |
| No | 568 (93.6%) | 39 (6.4%) |  |  |
| Yes | 10 (100%) | 0 (0%) |  | - |
| *Missing* | 30 | 2 |  |  |
| Diabetic |  |  | 0.2986 |  |
| No | 512 (93.1%) | 38 (6.9%) |  |  |
| Yes | 68 (97.1%) | 2 (2.9%) |  | 0.49 [0.1-1.49]\*\* |
| *Missing* | 28 | 1 |  |  |
| Currently treated for diabetes |  |  | 0.239 |  |
| No | 530 (93.1%) | 39 (6.9%) |  |  |
| Yes | 50 (98%) | 1 (2%) |  | 0.4 [0.04-1.54]\*\* |
| *Missing* | 28 | 1 |  |  |
| Heart or circulatory condition |  |  | 0.1714 |  |
| No | 397 (92.5%) | 32 (7.5%) |  |  |
| Yes | 184 (95.8%) | 8 (4.2%) |  | 0.54 [0.23-1.14] |
| *Missing* | 27 | 1 |  |  |
| High blood pressure |  |  | 0.1373 |  |
| No | 424 (92.6%) | 34 (7.4%) |  |  |
| Yes | 157 (96.3%) | 6 (3.7%) |  | 0.48 [0.18-1.08] |
| *Missing* | 27 | 1 |  |  |
| Myocardial infarction |  |  | 0.6263 |  |
| No | 562 (93.4%) | 40 (6.6%) |  |  |
| Yes | 19 (100%) | 0 (0%) |  | - |
| *Missing* | 27 | 1 |  |  |
| Heart failure |  |  | 1 |  |
| No | 577 (93.5%) | 40 (6.5%) |  |  |
| Yes | 4 (100%) | 0 (0%) |  | - |
| *Missing* | 27 | 1 |  |  |
| Coronary heart disease |  |  | 1 |  |
| No | 568 (93.4%) | 40 (6.6%) |  |  |
| Yes | 13 (100%) | 0 (0%) |  | - |
| *Missing* | 27 | 1 |  |  |
| Atrial fibrillation |  |  | 0.6388 |  |
| No | 562 (93.7%) | 38 (6.3%) |  |  |
| Yes | 19 (90.5%) | 2 (9.5%) |  | 1.87 [0.37-6.19]\*\* |
| *Missing* | 27 | 1 |  |  |
| Angina |  |  | 1 |  |
| No | 567 (93.4%) | 40 (6.6%) |  |  |
| Yes | 14 (100%) | 0 (0%) |  | - |
| *Missing* | 27 | 1 |  |  |
| Valvular heart disease |  |  | 0.284 |  |
| No | 577 (93.7%) | 39 (6.3%) |  |  |
| Yes | 4 (80%) | 1 (20%) |  | 4.87 [0.48-27.16]\*\* |
| *Missing* | 27 | 1 |  |  |
| High blood pressure treatment |  |  | 0.0968 |  |
| No | 424 (92.6%) | 34 (7.4%) |  |  |
| Yes | 150 (96.8%) | 5 (3.2%) |  | 0.42 [0.14-0.99] |
| *Missing* | 34 | 2 |  |  |
| Myocardial infarction treatment |  |  | 1 |  |
| No | 562 (93.4%) | 40 (6.6%) |  |  |
| Yes | 11 (100%) | 0 (0%) |  | - |
| *Missing* | 35 | 1 |  |  |
| Heart failure treatment |  |  | 1 |  |
| No | 577 (93.5%) | 40 (6.5%) |  |  |
| Yes | 3 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Coronary heart disease treatment |  |  | 1 |  |
| No | 568 (93.4%) | 40 (6.6%) |  |  |
| Yes | 10 (100%) | 0 (0%) |  | - |
| *Missing* | 30 | 1 |  |  |
| Atrial fibrillation treatment |  |  | 0.2544 |  |
| No | 562 (93.7%) | 38 (6.3%) |  |  |
| Yes | 13 (86.7%) | 2 (13.3%) |  | 2.71 [0.52-9.36]\*\* |
| *Missing* | 33 | 1 |  |  |
| Angina treatment |  |  | 1 |  |
| No | 567 (93.4%) | 40 (6.6%) |  |  |
| Yes | 10 (100%) | 0 (0%) |  | - |
| *Missing* | 31 | 1 |  |  |
| Respiratory system condition |  |  | 1 |  |
| No | 406 (93.5%) | 28 (6.5%) |  |  |
| Yes | 175 (93.6%) | 12 (6.4%) |  | 0.99 [0.48-1.96] |
| *Missing* | 27 | 1 |  |  |
| Asthma |  |  | 0.2787 |  |
| No | 476 (93%) | 36 (7%) |  |  |
| Yes | 105 (96.3%) | 4 (3.7%) |  | 0.5 [0.15-1.29] |
| *Missing* | 27 | 1 |  |  |
| COPD |  |  | 0.2515 |  |
| No | 550 (93.2%) | 40 (6.8%) |  |  |
| Yes | 31 (100%) | 0 (0%) |  | - |
| *Missing* | 27 | 1 |  |  |
| Interstitial lung disease |  |  | 1 |  |
| No | 579 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 27 | 1 |  |  |
| Chronic bronchitis |  |  | 0.6808 |  |
| No | 557 (93.6%) | 38 (6.4%) |  |  |
| Yes | 24 (92.3%) | 2 (7.7%) |  | 1.48 [0.29-4.78]\*\* |
| *Missing* | 27 | 1 |  |  |
| Emphysema |  |  | 0.4148 |  |
| No | 574 (93.6%) | 39 (6.4%) |  |  |
| Yes | 7 (87.5%) | 1 (12.5%) |  | 2.91 [0.3-13.8]\*\* |
| *Missing* | 27 | 1 |  |  |
| Sleep apnea |  |  | 0.4666 |  |
| No | 510 (93.9%) | 33 (6.1%) |  |  |
| Yes | 71 (91%) | 7 (9%) |  | 1.52 [0.6-3.39] |
| *Missing* | 27 | 1 |  |  |
| Asthma treatment |  |  | 0.432 |  |
| No | 476 (93%) | 36 (7%) |  |  |
| Yes | 74 (96.1%) | 3 (3.9%) |  | 0.54 [0.13-1.53] |
| *Missing* | 58 | 2 |  |  |
| COPD treatment |  |  | 0.388 |  |
| No | 550 (93.2%) | 40 (6.8%) |  |  |
| Yes | 22 (100%) | 0 (0%) |  | - |
| *Missing* | 36 | 1 |  |  |
| Interstitial lung disease treatment |  |  | 1 |  |
| No | 579 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 27 | 1 |  |  |
| Chronic bronchitis treatment |  |  | 1 |  |
| No | 557 (93.6%) | 38 (6.4%) |  |  |
| Yes | 9 (100%) | 0 (0%) |  | - |
| *Missing* | 42 | 3 |  |  |
| Emphysema treatment |  |  | 1 |  |
| No | 574 (93.6%) | 39 (6.4%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 32 | 2 |  |  |
| Sleep apnea treatment |  |  | 0.574 |  |
| No | 510 (93.9%) | 33 (6.1%) |  |  |
| Yes | 56 (91.8%) | 5 (8.2%) |  | 1.48 [0.52-3.54]\*\* |
| *Missing* | 42 | 3 |  |  |
| Gastrointestinal condition |  |  | 0.4165 |  |
| No | 518 (93.2%) | 38 (6.8%) |  |  |
| Yes | 62 (96.9%) | 2 (3.1%) |  | 0.54 [0.11-1.66]\*\* |
| *Missing* | 28 | 1 |  |  |
| Chrohn's disease |  |  | 1 |  |
| No | 576 (93.5%) | 40 (6.5%) |  |  |
| Yes | 4 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Ulcerative colitis |  |  | 1 |  |
| No | 575 (93.5%) | 40 (6.5%) |  |  |
| Yes | 5 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Irritable bowel syndrome |  |  | 0.239 |  |
| No | 530 (93.1%) | 39 (6.9%) |  |  |
| Yes | 50 (98%) | 1 (2%) |  | 0.4 [0.04-1.54]\*\* |
| *Missing* | 28 | 1 |  |  |
| Celiac disease |  |  | 0.2844 |  |
| No | 576 (93.7%) | 39 (6.3%) |  |  |
| Yes | 4 (80%) | 1 (20%) |  | 4.86 [0.48-27.11]\*\* |
| *Missing* | 28 | 1 |  |  |
| Chrohn's disease treatment |  |  | 1 |  |
| No | 576 (93.5%) | 40 (6.5%) |  |  |
| Yes | 3 (100%) | 0 (0%) |  | - |
| *Missing* | 29 | 1 |  |  |
| Ulcerative colitis treatment |  |  | 1 |  |
| No | 575 (93.5%) | 40 (6.5%) |  |  |
| Yes | 3 (100%) | 0 (0%) |  | - |
| *Missing* | 30 | 1 |  |  |
| Irritable bowel syndrome treatment |  |  | 0.6161 |  |
| No | 530 (93.1%) | 39 (6.9%) |  |  |
| Yes | 16 (100%) | 0 (0%) |  | - |
| *Missing* | 62 | 2 |  |  |
| Celiac disease treatment |  |  | 0.235 |  |
| No | 576 (93.7%) | 39 (6.3%) |  |  |
| Yes | 3 (75%) | 1 (25%) |  | 6.25 [0.6-39.13]\*\* |
| *Missing* | 29 | 1 |  |  |
| Liver or pancreas disease |  |  | 0.0397 |  |
| No | 527 (92.9%) | 40 (7.1%) |  |  |
| Yes | 53 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Liver cirrhosis |  |  | 1 |  |
| No | 579 (93.5%) | 40 (6.5%) |  |  |
| Yes | 1 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Chronic hepatitis |  |  | 1 |  |
| No | 578 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| NAFLD / NASH |  |  | 0.0647 |  |
| No | 530 (93%) | 40 (7%) |  |  |
| Yes | 50 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Liver cirrhosis treatment |  |  | 1 |  |
| No | 579 (93.5%) | 40 (6.5%) |  |  |
| Yes | 1 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| NAFLD / NASH treatment |  |  | 1 |  |
| No | 530 (93%) | 40 (7%) |  |  |
| Yes | 5 (100%) | 0 (0%) |  | - |
| *Missing* | 73 | 1 |  |  |
| Renal disease |  |  | 1 |  |
| No | 578 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Chronic renal failure |  |  | 1 |  |
| No | 578 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Mental health condition |  |  | 1 |  |
| No | 578 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Neurological condition |  |  | 1 |  |
| No | 566 (93.6%) | 39 (6.4%) |  |  |
| Yes | 14 (93.3%) | 1 (6.7%) |  | 1.48 [0.16-6.27]\*\* |
| *Missing* | 28 | 1 |  |  |
| Thrombotic stroke |  |  | 0.3309 |  |
| No | 575 (93.6%) | 39 (6.4%) |  |  |
| Yes | 5 (83.3%) | 1 (16.7%) |  | 3.97 [0.4-20.58]\*\* |
| *Missing* | 28 | 1 |  |  |
| Hemorrhagic stroke |  |  | 1 |  |
| No | 578 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Stroke |  |  | 0.3745 |  |
| No | 574 (93.6%) | 39 (6.4%) |  |  |
| Yes | 6 (85.7%) | 1 (14.3%) |  | 3.36 [0.34-16.53]\*\* |
| *Missing* | 28 | 1 |  |  |
| Multiple sclerosis |  |  | 1 |  |
| No | 572 (93.5%) | 40 (6.5%) |  |  |
| Yes | 8 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Thrombotic stroke treatment |  |  | 1 |  |
| No | 575 (93.6%) | 39 (6.4%) |  |  |
| Yes | 5 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 2 |  |  |
| Hemorrhagic stroke treatment |  |  | 1 |  |
| No | 578 (93.5%) | 40 (6.5%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Stroke treatment |  |  | 1 |  |
| No | 574 (93.6%) | 39 (6.4%) |  |  |
| Yes | 6 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 2 |  |  |
| Multiple sclerosis treatment |  |  | 1 |  |
| No | 572 (93.5%) | 40 (6.5%) |  |  |
| Yes | 5 (100%) | 0 (0%) |  | - |
| *Missing* | 31 | 1 |  |  |
| Arthritis disease |  |  | 0.4441 |  |
| No | 488 (93.1%) | 36 (6.9%) |  |  |
| Yes | 92 (95.8%) | 4 (4.2%) |  | 0.59 [0.17-1.52] |
| *Missing* | 28 | 1 |  |  |
| Rheumatoid arthritis |  |  | 1 |  |
| No | 557 (93.5%) | 39 (6.5%) |  |  |
| Yes | 23 (95.8%) | 1 (4.2%) |  | 0.9 [0.1-3.63]\*\* |
| *Missing* | 28 | 1 |  |  |
| Osteoarthritis |  |  | 0.5016 |  |
| No | 544 (93.3%) | 39 (6.7%) |  |  |
| Yes | 36 (97.3%) | 1 (2.7%) |  | 0.57 [0.06-2.22]\*\* |
| *Missing* | 28 | 1 |  |  |
| Rheumatoid arthritis treatment |  |  | 0.5228 |  |
| No | 570 (93.6%) | 39 (6.4%) |  |  |
| Yes | 10 (90.9%) | 1 (9.1%) |  | 2.06 [0.22-9.14]\*\* |
| *Missing* | 28 | 1 |  |  |
| Osteoarthritis treatment |  |  | 0.6156 |  |
| No | 563 (93.4%) | 40 (6.6%) |  |  |
| Yes | 16 (100%) | 0 (0%) |  | - |
| *Missing* | 29 | 1 |  |  |
| Bone and joint condition |  |  | 0.2374 |  |
| No | 471 (92.9%) | 36 (7.1%) |  |  |
| Yes | 109 (96.5%) | 4 (3.5%) |  | 0.48 [0.14-1.23] |
| *Missing* | 28 | 1 |  |  |
| Fibromyalgia |  |  | 0.3893 |  |
| No | 557 (93.3%) | 40 (6.7%) |  |  |
| Yes | 23 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Fibromyalgia |  |  | 0.6222 |  |
| No | 557 (93.3%) | 40 (6.7%) |  |  |
| Yes | 18 (100%) | 0 (0%) |  | - |
| *Missing* | 33 | 1 |  |  |
| Skin condition |  |  | 0.2985 |  |
| No | 477 (93%) | 36 (7%) |  |  |
| Yes | 103 (96.3%) | 4 (3.7%) |  | 0.51 [0.15-1.32] |
| *Missing* | 28 | 1 |  |  |
| Eczema |  |  | 0.0725 |  |
| No | 508 (92.9%) | 39 (7.1%) |  |  |
| Yes | 72 (98.6%) | 1 (1.4%) |  | 0.27 [0.03-1.02]\*\* |
| *Missing* | 28 | 1 |  |  |
| Psoriasis |  |  | 0.3492 |  |
| No | 541 (93.8%) | 36 (6.2%) |  |  |
| Yes | 39 (90.7%) | 4 (9.3%) |  | 1.69 [0.53-4.33]\*\* |
| *Missing* | 28 | 1 |  |  |
| Eczema treatment |  |  | 0.7122 |  |
| No | 508 (92.9%) | 39 (7.1%) |  |  |
| Yes | 27 (96.4%) | 1 (3.6%) |  | 0.7 [0.08-2.8]\*\* |
| *Missing* | 73 | 1 |  |  |
| Psoriasis treatment |  |  | 0.0857 |  |
| No | 541 (93.8%) | 36 (6.2%) |  |  |
| Yes | 22 (84.6%) | 4 (15.4%) |  | 2.97 [0.9-7.96]\*\* |
| *Missing* | 45 | 1 |  |  |
| Immune system condition |  |  | 0.2472 |  |
| No | 553 (93.3%) | 40 (6.7%) |  |  |
| Yes | 27 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| HIV |  |  | 1 |  |
| No | 577 (93.5%) | 40 (6.5%) |  |  |
| Yes | 3 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Weakened/compromised immune system |  |  | 1 |  |
| No | 573 (93.5%) | 40 (6.5%) |  |  |
| Yes | 7 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Hashimotos thyroiditis, Sjögrens syndrome, Ankylosing spondylitis |  |  | 0.6179 |  |
| No | 563 (93.4%) | 40 (6.6%) |  |  |
| Yes | 17 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| HIV treatment |  |  | 1 |  |
| No | 577 (93.5%) | 40 (6.5%) |  |  |
| Yes | 3 (100%) | 0 (0%) |  | - |
| *Missing* | 28 | 1 |  |  |
| Weakened/compromised immune system treatment |  |  | 1 |  |
| No | 573 (93.5%) | 40 (6.5%) |  |  |
| Yes | 4 (100%) | 0 (0%) |  | - |
| *Missing* | 31 | 1 |  |  |
| Hashimotos thyroiditis, Sjögrens syndrome, Ankylosing spondylitis treatment |  |  | 1 |  |
| No | 563 (93.4%) | 40 (6.6%) |  |  |
| Yes | 14 (100%) | 0 (0%) |  | - |
| *Missing* | 31 | 1 |  |  |
| Seasonal influenza vaccination in 2019 / 2020 |  |  | 1 |  |
| No | 326 (93.7%) | 22 (6.3%) |  |  |
| Yes | 253 (93.4%) | 18 (6.6%) |  | 1.05 [0.55-2] |
| *Missing* | 29 | 1 |  |  |
| BCG vaccination |  |  | 0.8194 |  |
| Yes | 277 (92.6%) | 22 (7.4%) |  | 1.16 [0.57-2.49] |
| No | 176 (93.6%) | 12 (6.4%) |  |  |
| *Missing* | 155 | 7 |  |  |
| Received an organ, bone marrow, or stem cell transplant |  |  | 0.2381 |  |
| No | 567 (93.6%) | 39 (6.4%) |  |  |
| Yes | 3 (75%) | 1 (25%) |  | 6.16 [0.59-38.52]\*\* |
| *Missing* | 38 | 1 |  |  |
| ACE-inhibitors class |  |  | 0.6079 |  |
| No | 539 (93.4%) | 38 (6.6%) |  |  |
| Yes | 69 (95.8%) | 3 (4.2%) |  | 0.71 [0.19-1.91]\*\* |
| *Missing* | 0 | 0 |  |  |
| Angiotensin II Receptor Blockers |  |  | 0.3022 |  |
| No | 537 (93.2%) | 39 (6.8%) |  |  |
| Yes | 71 (97.3%) | 2 (2.7%) |  | 0.48 [0.1-1.45]\*\* |
| *Missing* | 0 | 0 |  |  |
| Antibiotics |  |  | 0.6492 |  |
| No | 447 (93.3%) | 32 (6.7%) |  |  |
| Yes | 161 (94.7%) | 9 (5.3%) |  | 0.78 [0.34-1.61] |
| *Missing* | 0 | 0 |  |  |
| Antivirals |  |  | 1 |  |
| No | 585 (93.6%) | 40 (6.4%) |  |  |
| Yes | 23 (95.8%) | 1 (4.2%) |  | 0.92 [0.1-3.71]\*\* |
| *Missing* | 0 | 0 |  |  |
| Allergy medications |  |  | 0.528 |  |
| No | 439 (93.2%) | 32 (6.8%) |  |  |
| Yes | 169 (94.9%) | 9 (5.1%) |  | 0.73 [0.32-1.5] |
| *Missing* | 0 | 0 |  |  |
| Androgen deprivation therapy |  |  | 1 |  |
| No | 606 (93.7%) | 41 (6.3%) |  |  |
| Yes | 2 (100%) | 0 (0%) |  | - |
| *Missing* | 0 | 0 |  |  |
| Asthma medications |  |  | 0.6379 |  |
| No | 509 (93.4%) | 36 (6.6%) |  |  |
| Yes | 99 (95.2%) | 5 (4.8%) |  | 0.71 [0.24-1.71] |
| *Missing* | 0 | 0 |  |  |
| Immunosuppressive/immunomodulatory medication |  |  | 0.507 |  |
| No | 567 (93.4%) | 40 (6.6%) |  |  |
| Yes | 41 (97.6%) | 1 (2.4%) |  | 0.51 [0.06-1.97]\*\* |
| *Missing* | 0 | 0 |  |  |
| Blood thinners |  |  | 0.7379 |  |
| No | 570 (93.8%) | 38 (6.2%) |  |  |
| Yes | 38 (92.7%) | 3 (7.3%) |  | 1.35 [0.36-3.73]\*\* |
| *Missing* | 0 | 0 |  |  |
| Non-steroidal anti-inflammatory drugs |  |  | 0.7517 |  |
| No | 320 (94.1%) | 20 (5.9%) |  |  |
| Yes | 288 (93.2%) | 21 (6.8%) |  | 1.17 [0.62-2.21] |
| *Missing* | 0 | 0 |  |  |
| Other pain/fever relievers |  |  | 0.4074 |  |
| Yes | 383 (93%) | 29 (7%) |  | 1.42 [0.73-2.94] |
| No | 225 (94.9%) | 12 (5.1%) |  |  |
| *Missing* | 0 | 0 |  |  |
| Anosmia |  |  | <0.0001 \* |  |
| No | 548 (97.2%) | 16 (2.8%) |  |  |
| Yes | 47 (65.3%) | 25 (34.7%) |  | 17.85 [9.07-36.08]\*\* |
| *Missing* | 13 | 0 |  |  |
| Ageusia |  |  | <0.0001 \* |  |
| No | 550 (97.2%) | 16 (2.8%) |  |  |
| Yes | 45 (64.3%) | 25 (35.7%) |  | 18.7 [9.48-37.9]\*\* |
| *Missing* | 13 | 0 |  |  |
| Anosmia or ageusia |  |  | <0.0001 \* |  |
| No | 536 (97.3%) | 15 (2.7%) |  |  |
| Yes | 59 (69.4%) | 26 (30.6%) |  | 15.75 [8-32.07] |
| *Missing* | 13 | 0 |  |  |
| Wet cough |  |  | 0.4944 |  |
| No | 506 (93.2%) | 37 (6.8%) |  |  |
| Yes | 89 (95.7%) | 4 (4.3%) |  | 0.61 [0.18-1.58] |
| *Missing* | 13 | 0 |  |  |
| Dry cough |  |  | 0.001 \* |  |
| No | 462 (95.5%) | 22 (4.5%) |  |  |
| Yes | 133 (87.5%) | 19 (12.5%) |  | 3 [1.56-5.71] |
| *Missing* | 13 | 0 |  |  |
| Cough |  |  | 0.0455 |  |
| No | 416 (95%) | 22 (5%) |  |  |
| Yes | 179 (90.4%) | 19 (9.6%) |  | 2.01 [1.05-3.8] |
| *Missing* | 13 | 0 |  |  |
| Fatigue |  |  | <0.0001 \* |  |
| No | 515 (97%) | 16 (3%) |  |  |
| Yes | 81 (76.4%) | 25 (23.6%) |  | 9.93 [5.13-19.76] |
| *Missing* | 12 | 0 |  |  |
| Loss of appetite |  |  | <0.0001 \* |  |
| No | 578 (94.6%) | 33 (5.4%) |  |  |
| Yes | 18 (69.2%) | 8 (30.8%) |  | 7.93 [3.14-18.78]\*\* |
| *Missing* | 12 | 0 |  |  |
| Fever |  |  | <0.0001 \* |  |
| No | 419 (97%) | 13 (3%) |  |  |
| Yes | 134 (83.2%) | 27 (16.8%) |  | 6.49 [3.32-13.33] |
| *Missing* | 55 | 1 |  |  |
| Rhinitis |  |  | 0.2489 |  |
| No | 566 (93.2%) | 41 (6.8%) |  |  |
| Yes | 30 (100%) | 0 (0%) |  | - |
| *Missing* | 12 | 0 |  |  |
| Sinus pain |  |  | 0.4638 |  |
| No | 565 (93.7%) | 38 (6.3%) |  |  |
| Yes | 30 (90.9%) | 3 (9.1%) |  | 1.69 [0.44-4.75]\*\* |
| *Missing* | 13 | 0 |  |  |
| Ear pain |  |  | 0.3742 |  |
| No | 589 (93.6%) | 40 (6.4%) |  |  |
| Yes | 6 (85.7%) | 1 (14.3%) |  | 3.36 [0.34-16.52]\*\* |
| *Missing* | 13 | 0 |  |  |
| Sore throat |  |  | 1 |  |
| No | 560 (93.5%) | 39 (6.5%) |  |  |
| Yes | 35 (94.6%) | 2 (5.4%) |  | 1 [0.2-3.14]\*\* |
| *Missing* | 13 | 0 |  |  |
| Hoarseness |  |  | 0.0532 |  |
| No | 401 (95%) | 21 (5%) |  |  |
| Yes | 195 (90.7%) | 20 (9.3%) |  | 1.96 [1.03-3.71] |
| *Missing* | 12 | 0 |  |  |
| Shortness of breath or difficulty breathing |  |  | <0.0001 \* |  |
| No | 409 (96.5%) | 15 (3.5%) |  |  |
| Yes | 187 (87.8%) | 26 (12.2%) |  | 3.79 [1.99-7.49] |
| *Missing* | 12 | 0 |  |  |
| Headache |  |  | <0.0001 \* |  |
| No | 546 (95.8%) | 24 (4.2%) |  |  |
| Yes | 50 (74.6%) | 17 (25.4%) |  | 7.73 [3.88-15.18]\*\* |
| *Missing* | 12 | 0 |  |  |
| General muscle and/or joint aches and pains |  |  | 1e-04 \* |  |
| No | 556 (94.9%) | 30 (5.1%) |  |  |
| Yes | 40 (78.4%) | 11 (21.6%) |  | 5.18 [2.37-10.74]\*\* |
| *Missing* | 12 | 0 |  |  |
| Chills or shivering |  |  | <0.0001 \* |  |
| No | 418 (96.8%) | 14 (3.2%) |  |  |
| Yes | 178 (86.8%) | 27 (13.2%) |  | 4.53 [2.36-9.08] |
| *Missing* | 12 | 0 |  |  |
| Diarrhea |  |  | 0.0884 |  |
| No | 572 (93.9%) | 37 (6.1%) |  |  |
| Yes | 23 (85.2%) | 4 (14.8%) |  | 2.92 [0.89-7.79]\*\* |
| *Missing* | 13 | 0 |  |  |
| Vomiting |  |  | 0.0175 |  |
| No | 558 (94.3%) | 34 (5.7%) |  |  |
| Yes | 37 (84.1%) | 7 (15.9%) |  | 3.24 [1.29-7.29]\*\* |
| *Missing* | 13 | 0 |  |  |
| Nausea |  |  | <0.0001 \* |  |
| No | 471 (95.7%) | 21 (4.3%) |  |  |
| Yes | 125 (86.2%) | 20 (13.8%) |  | 3.59 [1.88-6.85] |
| *Missing* | 12 | 0 |  |  |

ACE: Angiotensin converting enzyme; BCG: Bacillus Calmette–Guérin; CI: confidence interval; COPD: Chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-Alcoholic Steatohepatitis

\* significant p-values after the Benjamini & Hochberg step-up false discovery rate-controlling procedure

\*\* Expected < 5 individuals: Firth's bias-Reduced penalized-likelihood logistic regression

\*\*\* medical condition currently treated among the following list: cardiovascular diseases (HBP, coronary artery disease,..), auto-immune diseases, diabetes, infectious disease, gastrointestinal and liver diseases, cancers, renal diseases.